product name UM729
Description: UM729 (also known as C07) is an enhancer of aryl hydrocarbon receptor (AhR) antagonists. UM-729 enhances the self-renewal of human hematopoietic stem cells in vitro. UM729 has been found to be a new pyrimidoindole and have an additive efficacy with AhR antagonists in preventing differentiation in most AML specimen. In addition, UM729 has been reported to expand mormal HSPCs in a AhR-independent fashion.
References: Nat Methods. 2014 Apr;11(4):436-42.
367.44
Formula
C19H19N5O
CAS No.
1448723-60-1
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 48 mg/mL (130.6 mM)
Water: <1 mg/mL
Ethanol: 9 mg/mL (24.5 mM)
Solubility (In vivo)
Synonyms
C07
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19393168
| In Vitro |
In vitro activity: UM729 expands normal hematopoietic stem and progenitor cells (HSPCs) in an AhR-independent manner. UM729 prevents the AML cell differentiation. In cultured 05H163 cells, compared with AhR suppressors (flavonoid, benzothiophene, and β-carboline) alone, addition of UM729 improves the numbers of CD34+CD15– cells. UM729 has an additive effect with AhR antagonists in preventing differentiation in most AML specimens. Kinase Assay: Cell Assay: CellTrace Violet is added at a final concentration of 3 µM to cell suspensions (107 cells/mL) containing SR1 (500 nM), UM729 (1 µM), both compounds or vehicle (0.1% DMSO). CellTrace Violet–labeled cells are stained with surface antibodies to human CD3, CD19, CD34 and CD33 on day 0, day 2 and day 4 before analysis on a flow cytometry. |
|---|---|
| In Vivo | In NSG mice, UM729 increases engraftment but not leukemic stem cell (LSC) frequency when administered alone or in combination with SR1. |
| Animal model | Female NSG mice |
| Formulation & Dosage | Dissolved in DMSO; 1 µM; i.v. |
| References | Nat Methods. 2014 Apr;11(4):436-42. |
Related Posts
product name UM729
Description: UM729 (also known as C07) is an enhancer of aryl hydrocarbon receptor (AhR) antagonists. UM-729 enhances the self-renewal of human hematopoietic stem cells in vitro. UM729 has been found to be a new pyrimidoindole and have an additive efficacy with AhR antagonists in preventing differentiation in most AML specimen. In addition, UM729 has been reported to expand mormal HSPCs in a AhR-independent fashion.
References: Nat Methods. 2014 Apr;11(4):436-42.
367.44
Formula
C19H19N5O
CAS No.
1448723-60-1
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 48 mg/mL (130.6 mM)
Water: <1 mg/mL
Ethanol: 9 mg/mL (24.5 mM)
Solubility (In vivo)
Synonyms
C07
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19393168
| In Vitro |
In vitro activity: UM729 expands normal hematopoietic stem and progenitor cells (HSPCs) in an AhR-independent manner. UM729 prevents the AML cell differentiation. In cultured 05H163 cells, compared with AhR suppressors (flavonoid, benzothiophene, and β-carboline) alone, addition of UM729 improves the numbers of CD34+CD15– cells. UM729 has an additive effect with AhR antagonists in preventing differentiation in most AML specimens. Kinase Assay: Cell Assay: CellTrace Violet is added at a final concentration of 3 µM to cell suspensions (107 cells/mL) containing SR1 (500 nM), UM729 (1 µM), both compounds or vehicle (0.1% DMSO). CellTrace Violet–labeled cells are stained with surface antibodies to human CD3, CD19, CD34 and CD33 on day 0, day 2 and day 4 before analysis on a flow cytometry. |
|---|---|
| In Vivo | In NSG mice, UM729 increases engraftment but not leukemic stem cell (LSC) frequency when administered alone or in combination with SR1. |
| Animal model | Female NSG mice |
| Formulation & Dosage | Dissolved in DMSO; 1 µM; i.v. |
| References | Nat Methods. 2014 Apr;11(4):436-42. |